Pluristem Therapeutics (PSTI) Initiates Final Validation of New Manufacturing Facility
12/27/2012 9:13:13 AM
HAIFA, Israel, Dec. 27, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today it has initiated the final validation steps for its new "state-of-the-art" manufacturing facility prior to taking possession of the facility. These steps include the validation of several installation systems including as heating, ventilation and air conditioning (HVAC), water, oil free air and sterile room systems.
comments powered by